Since the start of the ongoing outbreak, the cannabis industry has been the source of some debate as stakeholders and active consumers attempt to understand COVID-19’s far-reaching effects. Pulmonologists and lung experts have cautioned that inhaled smoke from combusted plant material – be it … Read more about Evidence Suggests CBD Potential in Treating COVID-19
FDA Delivers Latest CBD Study to Congress
On July 8, 2020, the U.S. Food and Drug Administration (“FDA”) delivered the results of its most comprehensive sampling study on the current cannabidiol (“CBD”) marketplace to the U.S. House Committee on Appropriations and the U.S. Senate Committee on Appropriations.1 Congress mandated FDA to … Read more about FDA Delivers Latest CBD Study to Congress
FTC Sues Company for Unsubstantiated Claims
On April 24, 2020, the Federal Trade Commission (“FTC”) filed a complaint in federal court as well as an administrative complaint against California-based marketer, Whole Leaf Organics for its unsubstantiated product claims.1 The company sells Thrive, a supplement consisting mainly of vitamin C and … Read more about FTC Sues Company for Unsubstantiated Claims
DEA Removes CBD from Controlled Substances Act
On Monday, April 6, GW Pharmaceuticals revealed that the company had received notice from the U.S. Drug Enforcement Administration (“DEA”) stating that its drug Epidiolex was no longer subject to the requirements of the Controlled Substances Act (“CSA”). In a company release announcing the agency … Read more about DEA Removes CBD from Controlled Substances Act
Vape and E-Cigarette Manufacturers Catch Another Break
This week, in a letter to federal Judge Paul Grimm, the U.S. Food and Drug Administration (“FDA”) requested a 120-day extension for e-cigarette product applications, citing the unforeseen impact of the novel coronavirus (“COVID-19”). This marks the most recent instance in a long line of delays, both … Read more about Vape and E-Cigarette Manufacturers Catch Another Break
FDA Proposes $5 Million Budget to Regulate CBD in 2021
President Trump’s budget proposal for the 2021 fiscal year, which is set to be presented to Congress next year, should he gain re-election, includes $6.2 billion in overall funding for the Food and Drug Administration (“FDA”). This proposal includes a $5 million-line item for FDA to continue … Read more about FDA Proposes $5 Million Budget to Regulate CBD in 2021
FDA Recognizes the Need for CBD Regulation
On February 26, 2020 the Food and Drug Administration’s (“FDA”) new commissioner, Dr. Stephen Hahn, acknowledged the growing consumer demand for CBD products. “People are using these [CBD] products,” Hahn said in his first public speech regarding CBD since taking office in December. “We are not … Read more about FDA Recognizes the Need for CBD Regulation
New Bill Proposes Solution to CBD Regulation
On January 13, 2020, the chairman of the U.S. House Committee on Agriculture, Representative Collin Peterson (D-MN), introduced a bill to address one of the largest issues in the burgeoning hemp industry – the regulation of cannabidiol (“CBD”). H.R.5587 aims to amend existing legislation to grant … Read more about New Bill Proposes Solution to CBD Regulation